Thurston Springer Miller Herd & Titak Inc. Cuts Stake in AbbVie Inc. $ABBV

Thurston Springer Miller Herd & Titak Inc. lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 94.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 719 shares of the company’s stock after selling 12,158 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in AbbVie were worth $166,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Marshall & Sullivan Inc. WA bought a new position in shares of AbbVie during the second quarter valued at about $25,000. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the 2nd quarter valued at about $26,000. TD Capital Management LLC boosted its holdings in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares during the period. Spurstone Advisory Services LLC bought a new position in AbbVie during the 2nd quarter worth approximately $28,000. Finally, Financial Gravity Companies Inc. bought a new position in AbbVie during the 2nd quarter worth approximately $36,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $224.32 on Thursday. The firm has a market capitalization of $396.47 billion, a price-to-earnings ratio of 169.94, a PEG ratio of 1.27 and a beta of 0.36. The stock has a fifty day moving average of $226.87 and a 200 day moving average of $210.61. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the business earned $3.00 EPS. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 496.97%.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent research reports. UBS Group boosted their price objective on AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a report on Monday, November 3rd. Guggenheim raised their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Finally, Scotiabank started coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $245.84.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.